Terms: = Pancreatic cancer AND PR, PGR, progesterone receptor
508 results:
1. Rutinosides-derived from Sarocladium strictum 6-O-α-rhamnosyl-β-glucosidase show enhanced anti-tumoral activity in pancreatic cancer cells.
Weiz G; González AL; Mansilla IS; Fernandez-Zapico ME; Molejón MI; Breccia JD
Microb Cell Fact; 2024 May; 23(1):133. PubMed ID: 38720294
[TBL] [Abstract] [Full Text] [Related]
2. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract] [Full Text] [Related]
4. Enhanced protein-metabolite correlation analysis: To investigate the association between Staphylococcus aureus mastitis and metabolic immune pathways.
Chen K; Hu B; Ren J; Deng X; Li Q; Zhang R; Zhang Y; Shen G; Liu S; Zhang J; Lu P
FASEB J; 2024 Apr; 38(7):e23587. PubMed ID: 38568835
[TBL] [Abstract] [Full Text] [Related]
5. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract] [Full Text] [Related]
6. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
8. Anti-collagenase, Anti-elastase, Anti-urease, and Anti-cancer Potentials of Isokaempferide as Natural Compound: In vitro and in silico Study.
Yin Q; Zhang H; Huang T; Liu B; Negm S; El-Kott AF
J Oleo Sci; 2024; 73(2):187-199. PubMed ID: 38311409
[TBL] [Abstract] [Full Text] [Related]
9. GAD2 Is a Highly Specific Marker for Neuroendocrine Neoplasms of the Pancreas.
Lennartz M; Benjamin Dünnebier N; Höflmayer D; Dwertmann Rico S; Kind S; Reiswich V; Viehweger F; Lutz F; Fraune C; Gorbokon N; Luebke AM; Hube-Magg C; Büscheck F; Menz A; Uhlig R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Steurer S; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C
Am J Surg Pathol; 2024 Apr; 48(4):377-386. PubMed ID: 38271200
[TBL] [Abstract] [Full Text] [Related]
10. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract] [Full Text] [Related]
11. A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.
Sun X; Guo P; Wang N; Shi Y; Li Y
Comput Biol Med; 2024 Feb; 169():107907. PubMed ID: 38184863
[TBL] [Abstract] [Full Text] [Related]
12. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report.
Tong F; Sun Y; Zhu Y; Sha H; Ni J; Qi L; Gu Q; Zhu C; Xi W; Liu B; Kong W; Du J
Front Immunol; 2023; 14():1277810. PubMed ID: 38179049
[TBL] [Abstract] [Full Text] [Related]
13. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Significance of Multi-cancer Genome Profiling: Data from a Single Hospital in Japan.
Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
[TBL] [Abstract] [Full Text] [Related]
15. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
16. Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.
Zhang C; Lizalek JM; Dougherty C; Westmark DM; Klute KA; Reames BN
Ann Surg Oncol; 2024 Feb; 31(2):792-803. PubMed ID: 37952021
[TBL] [Abstract] [Full Text] [Related]
17. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant pancreatic cancer Cells.
Che PP; Gregori A; Bergonzini C; Ali M; Mantini G; Schmidt T; Finamore F; Rodrigues SMF; Frampton AE; McDonnell LA; Danen EH; Slotman BJ; Sminia P; Giovannetti E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1328-1343. PubMed ID: 37914140
[TBL] [Abstract] [Full Text] [Related]
18. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable pancreatic cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract] [Full Text] [Related]
19. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract] [Full Text] [Related]
20. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
Qi C; Xie T; Zhou J; Wang X; Gong J; Zhang X; Li J; Yuan J; Liu C; Shen L
J Hematol Oncol; 2023 Sep; 16(1):102. PubMed ID: 37689733
[TBL] [Abstract] [Full Text] [Related]
[Next]
